Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Improving Outcomes of Neuroprotection by Minocycline</title><author><name sortKey="Xue, Mengzhou" sort="Xue, Mengzhou" uniqKey="Xue M" first="Mengzhou" last="Xue">Mengzhou Xue</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Mikliaeva, Elena I" sort="Mikliaeva, Elena I" uniqKey="Mikliaeva E" first="Elena I." last="Mikliaeva">Elena I. Mikliaeva</name><affiliation><nlm:aff id="aff2">Clara Christie Centre for Mouse Genomics and Modelling of Human Disease, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Casha, Steve" sort="Casha, Steve" uniqKey="Casha S" first="Steve" last="Casha">Steve Casha</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Zygun, David" sort="Zygun, David" uniqKey="Zygun D" first="David" last="Zygun">David Zygun</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Department of Medicine, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Demchuk, Andrew" sort="Demchuk, Andrew" uniqKey="Demchuk A" first="Andrew" last="Demchuk">Andrew Demchuk</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Yong, V Wee" sort="Yong, V Wee" uniqKey="Yong V" first="V. Wee" last="Yong">V. Wee Yong</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20110416</idno><idno type="pmc">2832142</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832142</idno><idno type="RBID">PMC:2832142</idno><idno type="doi">10.2353/ajpath.2010.090361</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000517</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000517</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Improving Outcomes of Neuroprotection by Minocycline</title><author><name sortKey="Xue, Mengzhou" sort="Xue, Mengzhou" uniqKey="Xue M" first="Mengzhou" last="Xue">Mengzhou Xue</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Mikliaeva, Elena I" sort="Mikliaeva, Elena I" uniqKey="Mikliaeva E" first="Elena I." last="Mikliaeva">Elena I. Mikliaeva</name><affiliation><nlm:aff id="aff2">Clara Christie Centre for Mouse Genomics and Modelling of Human Disease, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Casha, Steve" sort="Casha, Steve" uniqKey="Casha S" first="Steve" last="Casha">Steve Casha</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Zygun, David" sort="Zygun, David" uniqKey="Zygun D" first="David" last="Zygun">David Zygun</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff4">Department of Medicine, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Demchuk, Andrew" sort="Demchuk, Andrew" uniqKey="Demchuk A" first="Andrew" last="Demchuk">Andrew Demchuk</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author><author><name sortKey="Yong, V Wee" sort="Yong, V Wee" uniqKey="Yong V" first="V. Wee" last="Yong">V. Wee Yong</name><affiliation><nlm:aff id="aff1">Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</nlm:aff></affiliation></author></analytic><series><title level="j">The American Journal of Pathology</title><idno type="ISSN">0002-9440</idno><idno type="eISSN">1525-2191</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Minocycline ameliorates deficits in models of acute and chronic neurological diseases, but many publications do not replicate these results. We tested the hypothesis that a key factor in achieving neurological benefits is the exposure of neural cells to local high concentrations of minocycline. This hypothesis was evaluated by using human neurons in culture and in a mouse model of intracerebral hemorrhage (ICH). In culture, neurons were very vulnerable to blood-induced toxicity, with 60% lost within 24 hours in an environment of 5% blood in culture medium. Minocycline reduced blood-induced neurotoxicity in a concentration-dependent manner. <bold><italic>In vivo</italic></bold>, the introduction of blood into the striatum of mice to simulate ICH resulted in a massive lesion by 24 hours. When minocycline was mixed with the blood used to inflict ICH, the resulting extent of neuropathology was significantly less than that achieved with intraperitoneal administration of medication. The combination of intracerebral and intraperitoneal minocycline improved neuroprotection compared with either alone. We then delayed minocycline treatment and injected it into the hematoma 1 hour after ICH. We found greater alleviation of brain damage and neuronal death with increasing concentrations of minocycline injected locally, which was reflected in limited behavioral and histological recovery. We conclude that the prospect of neuroprotection with minocycline is improved by high concentrations of minocycline delivered locally into the central nervous system with supplementation from systemic administration.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Pathol</journal-id><journal-title-group><journal-title>The American Journal of Pathology</journal-title></journal-title-group><issn pub-type="ppub">0002-9440</issn><issn pub-type="epub">1525-2191</issn><publisher><publisher-name>American Society for Investigative Pathology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20110416</article-id><article-id pub-id-type="pmc">2832142</article-id><article-id pub-id-type="publisher-id">AJPA60433</article-id><article-id pub-id-type="doi">10.2353/ajpath.2010.090361</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Articles</subject></subj-group></article-categories><title-group><article-title>Improving Outcomes of Neuroprotection by Minocycline</article-title><subtitle>Guides from Cell Culture and Intracerebral Hemorrhage in Mice</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Mengzhou</given-names></name><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff3" ref-type="aff">†</xref></contrib><contrib contrib-type="author"><name><surname>Mikliaeva</surname><given-names>Elena I.</given-names></name><xref rid="aff2" ref-type="aff">‡</xref></contrib><contrib contrib-type="author"><name><surname>Casha</surname><given-names>Steve</given-names></name><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff3" ref-type="aff">†</xref></contrib><contrib contrib-type="author"><name><surname>Zygun</surname><given-names>David</given-names></name><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff3" ref-type="aff">†</xref><xref rid="aff4" ref-type="aff">§</xref></contrib><contrib contrib-type="author"><name><surname>Demchuk</surname><given-names>Andrew</given-names></name><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff3" ref-type="aff">†</xref></contrib><contrib contrib-type="author"><name><surname>Yong</surname><given-names>V. Wee</given-names></name><email>vyong@ucalgary.ca</email><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff3" ref-type="aff">†</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label>*</label>Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada</aff><aff id="aff2"><label>‡</label>Clara Christie Centre for Mouse Genomics and Modelling of Human Disease, University of Calgary, Calgary, Alberta, Canada</aff><aff id="aff3"><label>†</label>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</aff><aff id="aff4"><label>§</label>Department of Medicine, University of Calgary, Calgary, Alberta, Canada</aff><author-notes><corresp id="cor1"><label>*</label>Address reprint requests to V. Wee Yong, Ph.D., University of Calgary, 3330 Hospital Drive, Calgary, Alberta T2N 4N1, Canada <email>vyong@ucalgary.ca</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2010</year></pub-date><volume>176</volume><issue>3</issue><fpage>1193</fpage><lpage>1202</lpage><history><date date-type="accepted"><day>17</day><month>11</month><year>2009</year></date></history><permissions><copyright-statement>© 2010 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>American Society for Investigative Pathology</copyright-holder></permissions><abstract><p>Minocycline ameliorates deficits in models of acute and chronic neurological diseases, but many publications do not replicate these results. We tested the hypothesis that a key factor in achieving neurological benefits is the exposure of neural cells to local high concentrations of minocycline. This hypothesis was evaluated by using human neurons in culture and in a mouse model of intracerebral hemorrhage (ICH). In culture, neurons were very vulnerable to blood-induced toxicity, with 60% lost within 24 hours in an environment of 5% blood in culture medium. Minocycline reduced blood-induced neurotoxicity in a concentration-dependent manner. <bold><italic>In vivo</italic></bold>, the introduction of blood into the striatum of mice to simulate ICH resulted in a massive lesion by 24 hours. When minocycline was mixed with the blood used to inflict ICH, the resulting extent of neuropathology was significantly less than that achieved with intraperitoneal administration of medication. The combination of intracerebral and intraperitoneal minocycline improved neuroprotection compared with either alone. We then delayed minocycline treatment and injected it into the hematoma 1 hour after ICH. We found greater alleviation of brain damage and neuronal death with increasing concentrations of minocycline injected locally, which was reflected in limited behavioral and histological recovery. We conclude that the prospect of neuroprotection with minocycline is improved by high concentrations of minocycline delivered locally into the central nervous system with supplementation from systemic administration.</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000517 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000517 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.29. |  |